KR20210093977A - 자살 유전자 - Google Patents

자살 유전자 Download PDF

Info

Publication number
KR20210093977A
KR20210093977A KR1020217018726A KR20217018726A KR20210093977A KR 20210093977 A KR20210093977 A KR 20210093977A KR 1020217018726 A KR1020217018726 A KR 1020217018726A KR 20217018726 A KR20217018726 A KR 20217018726A KR 20210093977 A KR20210093977 A KR 20210093977A
Authority
KR
South Korea
Prior art keywords
leu
ser
gly
ala
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217018726A
Other languages
English (en)
Korean (ko)
Inventor
케이티 레즈바니
엘리자베스 쉬팔
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68848450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210093977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Publication of KR20210093977A publication Critical patent/KR20210093977A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020217018726A 2018-11-19 2019-11-18 자살 유전자 Ceased KR20210093977A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862769405P 2018-11-19 2018-11-19
US62/769,405 2018-11-19
US201862773372P 2018-11-30 2018-11-30
US62/773,372 2018-11-30
US201962791464P 2019-01-11 2019-01-11
US62/791,464 2019-01-11
PCT/US2019/062009 WO2020106619A1 (en) 2018-11-19 2019-11-18 Suicide gene

Publications (1)

Publication Number Publication Date
KR20210093977A true KR20210093977A (ko) 2021-07-28

Family

ID=68848450

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018726A Ceased KR20210093977A (ko) 2018-11-19 2019-11-18 자살 유전자

Country Status (18)

Country Link
US (1) US20220023343A1 (https=)
EP (1) EP3883959A1 (https=)
JP (1) JP2022513099A (https=)
KR (1) KR20210093977A (https=)
CN (1) CN113272320A (https=)
AU (1) AU2019384115A1 (https=)
BR (1) BR112021009634A2 (https=)
CA (1) CA3120349A1 (https=)
CL (1) CL2021001300A1 (https=)
CO (1) CO2021007824A2 (https=)
EC (1) ECSP21044662A (https=)
IL (1) IL283242A (https=)
MX (1) MX2021005847A (https=)
PE (1) PE20211236A1 (https=)
PH (1) PH12021551142A1 (https=)
SG (1) SG11202105238YA (https=)
TW (1) TW202039538A (https=)
WO (1) WO2020106619A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311837A (en) 2021-10-20 2024-05-01 Takeda Pharmaceuticals Co Compositions targeting bcma and methods of use thereof
EP4493581A1 (en) * 2022-03-18 2025-01-22 University of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US6143866A (en) 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP5956982B2 (ja) * 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP4166148B1 (en) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
EA035898B1 (ru) * 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
AU2016306209B2 (en) * 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107337737B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107245107B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用
CN107312098B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107312097B (zh) * 2017-07-18 2020-06-16 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
CL2021001300A1 (es) 2022-03-18
MX2021005847A (es) 2021-09-23
IL283242A (en) 2021-07-29
SG11202105238YA (en) 2021-06-29
EP3883959A1 (en) 2021-09-29
PE20211236A1 (es) 2021-07-09
TW202039538A (zh) 2020-11-01
CO2021007824A2 (es) 2021-06-30
WO2020106619A1 (en) 2020-05-28
US20220023343A1 (en) 2022-01-27
PH12021551142A1 (en) 2021-10-25
CN113272320A (zh) 2021-08-17
CA3120349A1 (en) 2020-05-28
JP2022513099A (ja) 2022-02-07
ECSP21044662A (es) 2021-09-30
BR112021009634A2 (pt) 2021-08-10
AU2019384115A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2016256582B2 (en) Oncolytic adenovirus encoding a B7 protein
AU2019315440B2 (en) Improving the efficacy and safety of adoptive cellular therapies
KR102612367B1 (ko) G-단백질 커플화 수용체를 표적화하는 키메라 항원 수용체 및 그의 용도
US20200338194A1 (en) Chimeric antigen receptor (car) signalling system
US20230062612A1 (en) Safety switches for regulation of gene expression
KR102211177B1 (ko) 종양 표적치료용 인터루킨-15 융합 단백질
KR100895134B1 (ko) 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
CN114585641B (zh) 间皮素car及其用途
CA3006859A1 (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
HU229680B1 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
CN115243713A (zh) 用于递送修饰的淋巴细胞聚集体的方法和组合物
CN113150132B (zh) 一种抗SARS-CoV-2重组抗体及其应用
KR20160145789A (ko) 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
KR20210093977A (ko) 자살 유전자
KR20240073006A (ko) 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
JP2022510481A (ja) Ｐｄｃｄ－１ホーミングエンドヌクレアーゼバリアント
CN120981481A (zh) Cd19特异性抗体构建体以及它们的组合物
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
CN106636000A (zh) hESCs‑TK细胞系及其构建方法和应用
RU2822193C2 (ru) Мезотелиновые car-рецепторы и их применение
CN118451178A (zh) 用于同种异体细胞疗法的遗传修饰原代细胞
WO2025043172A1 (en) Modified cd47 proteins and their uses
KR20260057133A (ko) 조작된 cd47 단백질 및 이의 용도
AU2024264889A1 (en) Methods of dosing and administration of engineered islet cells
HK40014529A (en) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601